Cover Image
Read Now

Efficacy and comparative effectiveness of off-label use of atypical antipsychotics

Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe...

Full description

Bibliographic Details
Main Author: Shekelle, Paul G.
Corporate Authors: Southern California Evidence-Based Practice Center/RAND., United States Agency for Healthcare Research and Quality
Format: eBook
Language:English
Published: Rockville, MD Agency for Healthcare Research and Quality 2007, [2007]
Series:Comparative effectiveness review
Subjects:
Antipsychotic Agents / Adverse Effects
Off-label Use
Antipsychotic Agents / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02057nam a2200277 u 4500
001 EB000942923
003 EBX01000000000000000736513
005 00000000000000.0
007 tu|||||||||||||||||||||
008 150223 r ||| eng
100 1 |a Shekelle, Paul G. 
245 0 0 |a Efficacy and comparative effectiveness of off-label use of atypical antipsychotics  |h Elektronische Ressource  |c prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Southern California/RAND Evidence-based Practice Center ; investigators, Paul Shekelle ... [et al.] 
260 |a Rockville, MD  |b Agency for Healthcare Research and Quality  |c 2007, [2007] 
505 0 |a Includes bibliographical references 
653 |a Antipsychotic Agents / adverse effects 
653 |a Off-Label Use 
653 |a Antipsychotic Agents / therapeutic use 
710 2 |a Southern California Evidence-Based Practice Center/RAND. 
710 2 |a United States  |b Agency for Healthcare Research and Quality 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Comparative effectiveness review 
500 |a Title from PDF title page (viewed on July 25, 2011). - "January 2007.". - "Contract No. 290-02-0003." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK43235  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe geriatric agitation, depression, obsessive-compulsive disorder, posttraumatic stress disorder, and personality disorders. The atypicals have also been studied for the management of Tourette's syndrome and autism in children. The purpose of this report is to review the scientific evidence on the safety and effectiveness of such off-label uses 

Similar Items